June 2007
Volume 2, Issue 6
Fragment-based screening
     
Issue Sponsored by
Evotec


f1000biology

Drug Discovery Today    Latest issue    home      

evotec

FEATURED
CONFERENCES


Pharma-Bio Outsourcing Conference and Exhibition

Pharma-Bio Outsourcing Conference and Exhibition

NeuroDrug 2007
logo
NeuroDrug 2007

Biofine USA
logo
Biofine USA



Mark Whittaker
The View from Here
Mark Whittaker

Fragment-based drug discovery is a new rational approach to drug hunting that is being embraced by both pharmaceutical and biotech companies...
Read more...

Upcoming Issues


Issue 7 / July '07
Chemoinformatics

Issue 8 / August '07
Molecular modelling

Issue 9 / September '07
Orphan Diseases


Editor's Choice

Sign Up for email

Update your details

Unsubscribe

Contact Us


evotec
A review of 2006


  Top Reviews
The fragment-approach: An update

Bartoli S, Fincham CI and Fattori D
Drug Discovery Today: Technologies

Fragment-based drug discovery as a source of preliminary hits has become a significant alternative to conventional drug discovery. A large variety of elegant biophysical validation methods such as NMR, X-ray crystallography, mass spectrometry or a combination of these, are used to fully investigate the typically weak binding interactions between fragments and the target of interest...

Fragment-based lead discovery: leads by design
blank
Carr RA, Congreve M, Murray CW, Rees DC

Drug Discovery Today

Fragment-based lead discovery (also referred to as needles, shapes, binding elements, seed templates or scaffolds) is a new lead discovery approach in which much lower molecular weight (120–250Da) compounds are screened relative to HTS campaigns...

Hit discovery and hit-to-lead approaches

Keserű GM and Makara GM
Drug Discovery Today

Hit discovery technologies range from traditional high-throughput screening to affinity selection of large libraries, fragment-based techniques and computer-aided de novo design, many of which have been extensively reviewed. Development of quality leads using hit confirmation and hit-to-lead approaches present their own challenges, depending on the hit discovery method used to identify the initial hits...


 

Abstracts of Key Research Articles

Fragment-based drug design: how big is too big?
Hajduk PJ
J Med Chem. 2006;49(24):6972-6.

Deconstructing fragment-based inhibitor
discovery

Babaoglu K, Shoichet BK
Nat Chem Biol. 2006;2(12):720-3.

Druggability indices for protein targets derived from NMR-based screening data
Hajduk PJ, Huth JR, Fesik SW
J Med Chem. 2005;48(7):2518-25.

Discovery of low-molecular-weight ligands for the AF6 PDZ domain
Joshi M, Vargas C, Boisguerin P, Diehl A, Krause G, Schmieder P, Moelling K, Hagen V, Schade M, Oschkinat H
Angew Chem Int Ed Engl. 2006;45(23):3790-5.

Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis
Petros AM, Dinges J, Augeri DJ, Baumeister SA, Betebenner DA, Bures MG, Elmore SW, Hajduk PJ, Joseph MK, Landis SK, Nettesheim DG, Rosenberg SH, Shen W, Thomas S, Wang X, Zanze I, Zhang H, Fesik SW
J Med Chem. 2006;49(2):656-63.

NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding site
Bretonnet AS, Jochum A, Walker O, Krimm I, Goekjian P, Marcillat O, Lancelin JM.
J Med Chem. 2007;50(8):1865-75.

A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors
Chen J, Zhang Z, Stebbins JL, Zhang X, Hoffman R, Moore A, Pellecchia M
ACS Chem Biol. 2007;2(5):329-36.

Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery
Saxty G, Woodhead SJ, Berdini V, Davies TG, Verdonk ML, Wyatt PG, Boyle RG, Barford D, Downham R, Garrett MD, Carr RA
J Med Chem. 2007;50(10):2293-2296.

Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase
Congreve M, Aharony D, Albert J, Callaghan O, Campbell J, Carr RA, Chessari G, Cowan S, Edwards PD, Frederickson M, McMenamin R, Murray CW, Patel S, Wallis N
J Med Chem. 2007;50(6):1124-32.

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design
Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY
Nat Biotechnol. 2005;23(2):201-7.


Data Protection Notice:

This email has been sent to email-address from Elsevier Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, registered in England with registered number 1982084, using Email Reaction’s Technology and Platform.

You are receiving this email because you were a registered user of BioMedNet and requested to receive Gateway Alerts or are a subscriber to Drug Discovery Today. To unsubscribe from this email alert service or sign up for others, click here.

For all inquiries, problems or suggestions regarding this service, please contact DDT@drugdiscoverytoday.com

Copyright © 2007 Elsevier Ltd. All rights reserved. Please read the Elsevier Alerts Privacy Policy and the E-Mail Reaction Privacy Policy.